Efficacy and safety of inhaled bitolterol mesylate via metered-dose inhaler in children with asthma

Annals of Allergy, Asthma and Immunology

Volumn 76, Issue 1, 1996, Pages 27-35

  Bierman, C Warren ^a   Kemp, J P ^b   Nathan, R A ^c   Fernandez, Gus ^d  

^a Asthma Inc   (United States)

^b ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^c Asthma and Allergy Associates PC   (United States)

^d Dura Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BITOLTEROL;

ARTICLE; ASTHMA; BRONCHODILATATION; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TACHYCARDIA; TREMOR;

EID: 0030021363     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)63403-5     Document Type: Article

References (22)

1. Kass I, Mingo TS. Bitolterol mesylate (WIN 32784) aerosol: a new long acting bronchodilator with reduced chronotropic effect. Chest 1980;78:283-7.
2. 2-adrenergic bronchodilators for treatment of asthma. J Allergy Clin Immunol 1984;73: 32-43.
3. Kemp JP, Chervinsky P, Orgel HA, et al. Concomitant bitolterol mesylate aerosol and theophylline for asthma therapy, with 24-hour electrocardiographic monitoring. J Allergy Clin Immunol 1984;73:32-43.
4. Pinnas JL. Bitolterol compared with isoproterenol in non-corticosteroid dependent asthma. J Respir Dis [Suppl] 1985;132:58-60.
5. Nathan RA, Bodman SF, Storms WW, Mingo TS. Bitolterol mesylate aerosol in adults with steroid dependent asthma: a comparison with isoproterenol hydrochloride aerosol. Ann Allergy 1986;56:494-9.
6. Canny JC, Desmond JB, Reisman JJ, Levinson H. Childhood Asthma. In: Weiss EB, Stein M. ed. Bronchial asthma, mechanisms and therapeutics, Boston, MA: Little, Brown, and Company, 1993;1062-74.
7. Ellis EF. Asthma in infancy and childhood. In: Middleton E, Reed CE, Ellis EF, Adkinson NF, Jr, Yunginger JW. Allergy principles and practice, 3rd ed. St. Louis, MO: The C.V. Mosby Company, 1988;1037-42.
8. Canny GJ, Levinson H. Aerosolstherapeutic use and delivery in childhood asthma. Ann Allergy 1988;60: 11-9.
9. IMS. National Disease and Therapeutic Index. Plymouth Meeting. PA.4Q 1993:1643.
10. Ellis EF. Bronchodilator treatment of children. In: Jenne JW, Murphy S. Drug therapy for asthma. 1st ed. New York, New York: Marcel Dekker, Inc. 1987;837-53.
11. NHLBI National Asthma Education Program, Expert Panel Report: Guidelines for the diagnosis and management of asthma. Bethesda, MD. US Dept. of Health and Human Services. Publication No. 91-3042, 1991.
12. Nussbaum E, Eyzaquirre M, Galant SP. Dose-response relationship of inhaled metaproterenol sulfate in pre-school children with mild asthma. Pediatrics 1985;85:1072-5.
13. Pederson S. Aerosol treatment of bronchoconstriction in children with or without a tube spacer. N Engl J Med 1983;308:1328-30.
14. Beck R, Robertson C, Galdes-Seldt M, Levinson H. Combined salbutamol and ipratropium bromide by inhalation in the treatment of severe acute asthma. J Pediatr 1985;107:605-8.
15. Lee HS. Comparison of oral and aerosol adrenergic bronchodilators in asthma. J Pediatr 1981;99:805-7.
16. Welch MJ, Kemp JP, Bierman CW, et al. Comparison of bitolterol mesylate and isoproterenol by metered-dose inhaler for regular, long-term treatment in asthmatic children. Pediatrics 1989; 3:27-36.
17. Nathan RA, Bronsky EA, Dockhorn RJ, Kemp JP. Multicenter dose-ranging study of bitolterol mesylate solution for nebulization in children with asthma. Ann Allergy 1994;72:209-16.
18. Jenne JW, Ahrens RC. Pharmacokinetics of beta-adrenergic compounds. In: Jenne JW, Murphy S. Drug therapy for asthma. 1st ed. New York, New York: Marcel Dekker, Inc, 1987:241-43.
19. Walker SB, Kradjan WA, Bierman CW. Bitolterol mesylate: a beta adrenergic agent. Pharmacotherapy 1985;5: 127-34.
20. Simons FER.,Soni ER, Watson WTA, Becker AB. Bronchodilator and bronchoprotective effects of salmeterol in young patients with asthma. J Allergy Clin Immunol 1992;89:811-5.
21. Green CP, Price JF. Prevention of excercise induced asthma by inhaled salmeterol xinafoate. Arch Dis Child 1992;67:1014-7.
22. Verberne A, Lenney W, Kerrebijn K. A three way crossover study comparing twice daily dosing of salmeterol 25 and 50 μg with placebo in children with mild to moderate reversible airways disease [Abstract]. Am Rev Respir Dis 1991;143(4):A20.